Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use

Vaccine

Volumn 26, Issue 45, 2008, Pages 5684-5688

  Fasanella, A ^a   Tonello, F ^b   Garofolo, G ^a   Muraro, L ^b   Carattoli, A ^c   Adone, R ^c   Montecucco, C ^b  

^a ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA PUGLIA E DELLA BASILICATA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Anthrax; Inactive mutant toxins; Recombinant protective antigen; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; EDEMA FACTOR; MINERAL OIL; RECOMBINANT PROTECTIVE ANTIGEN; RECOMBINANT VACCINE; STERNE 34F2; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY PRODUCTION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EMULSION; IMMUNOGENICITY; LETHAL GENE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VACCINATION; VETERINARY MEDICINE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HUMANS; MUTATION; RABBITS; VACCINATION; VACCINES, SYNTHETIC; VETERINARY MEDICINE;

EID: 52949120304     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.026     Document Type: Article

References (28)

1. Aloni-Grinstein R., Gat O., Alboum Z., Velan B., Cohen S., and Shafferman A. Oral spore vaccine based on live attenuated nontoxigenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 73 (2005) 4043-4053
2. Buonavoglia D., Fasanella A., Sagazio P., Tempesta M., Iovane G., and Buonavoglia C. Persistence of antibodies to Mycoplasma agalactiae in vaccinated sheep. New Microbiol. 21 (1998) 209-212
3. Coker P.R., Smith K.L., Fellows P.F., Rybachuck G., Kousoulas K.G., and Hugh-Jones M.E. Bacillus anthracis virulence in guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. J Clin Microbiol 41 (2003) 1212-1218
4. Collier R.J., and Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 19 (2003) 45-70
5. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176 (2006) 1776-1783
6. Fasanella A., Losito S., Trotta T., Adone R., Massa S., Ciuchini F., et al. Detection of anthrax vaccine virulence factors by Polymerase Chain Reaction. Vaccine 19 (2001) 4214-4218
7. Fasanella A., Van Ert M., Altamura S.A., Garofolo G., Buonavoglia C., Leori G., et al. Molecular diversity among Bacillus anthracis isolates in Italy. J Clin Microbiol 43 (2005) 3398-3401
8. Fasanella A, Fabiano MP, Garofolo G, Losito S. Preliminary studies on recombinant protective antigen (rPA) vaccine against anthrax for veterinary use. In: Abstract of the international veterinary vaccines and diagnostic conference, Oslo, Norway, June 25-29, 2006. p. 69.
9. Firoved A.M., Miller G.F., Moayeri M., Kakkar R., Shen Y., Wiggins J.F., et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 167 (2005) 1309-1320
10. Friedlander A.M., Welkos S.L., and Ivins B.E. Anthrax vaccines. Curr Top Microbiol Immunol 271 (2002) 33-60
11. Gaur R., Gupta P., Banerjea A.C., and Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax. Toxin Vaccine 20 (2002) 2836-2839
12. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 (2006) 5950-5959
13. Guidelines for the Surveillance and Control of Anthrax in Human and Animals (1998). WHO/EMC/ZDI/98.6.
14. Hambleton P., Carman J.A., and Melling J. Anthrax: the disease in relation to vaccines. Vaccine 2 (1984) 125-132
15. Joellenbeck L, Zwanziger L, Durch J, Strom B, editors. Is it safe? Does it work? In: The anthrax vaccine. Washington, DC: National Academy Press; 2002.
16. Leppla S.H. Production and purification of anthrax toxin. Methods Enzymol 165 (1988) 103-116
17. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 (2004) 422-430
18. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L.M., Norris S.L.W., et al. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 (2004) 2530-2536
19. Office International des Epizooties. Manual of diagnostic tests and vaccines for terrestrial animals, 5th ed. Paris, France: Office International des Epizooties; 2004.
20. Pitt M., Little S., Ivins B., et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87 (1999) 304
21. Pitt M., Little S., Ivins B., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 (2001) 4768-4773
22. Quesnel-Hellmann A., Cleret A., Vidal D.R., and Tournier J.N. Evidence for adjuvanticity of anthrax edema toxin. Vaccine 24 (2006) 699-702
23. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., and Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100 (2003) 10925-10930
24. Smith H. Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria. Trends Microbiol 8 5 (2000) 199-200
25. Spencer R.C. Bacillus anthracis. J Clin Pathol 56 (2003) 182-187
26. Tonello F., Naletto L., Romanello V., Dal Molin F., and Montecucco C. Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of Bacillus anthracis. Biochem Biophys Res Commun 313 (2004) 496-502
27. Turner A.J., Galvin J.W., Rubira R.J., Condron R.J., and Bradley T. Experiences with vaccination and epidemiological investigations on an anthrax outbreak in Australia in 1997. J Appl Microbiol 87 (1997) 294-297
28. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 pt 6 (2001) 1677-1685